For answers to questions you may have, select any of the topics below.
NEXPLANON is indicated for use by women to prevent pregnancy.
Complications of Insertion and Removal
Broken or Bent Implants
Changes in Menstrual Bleeding Patterns
Ectopic Pregnancies
Thrombotic and Other Vascular Events
Ovarian Cysts
Carcinoma of the Breast and Reproductive Organs
Liver Disease
Elevated Blood Pressure
Gallbladder Disease
Carbohydrate and Lipid Metabolic Effects
Depressed Mood
Return to Ovulation
Fluid Retention
Contact Lenses
Clinical Trial Experience
Effects of Other Drugs on Hormonal Contraceptives
Substances decreasing the plasma concentrations of hormonal contraceptives and potentially diminishing the efficacy of hormonal contraceptives:
Substances increasing the plasma concentrations of hormonal contraceptives:
Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) protease inhibitors and non-nucleoside reverse transcriptase inhibitors:
Effects of Hormonal Contraceptives on Other Drugs
USE IN SPECIFIC POPULATIONS
Pregnancy
Lactation
Pediatric Use
Overweight Women
Users of progestin-only contraceptives are likely to have changes in bleeding patterns. Based on data from clinical trials of the non-radiopaque etonogestrel implant (IMPLANON®)1:
Percentages of 90-day intervals with these bleeding patterns during the first 2 years of use in clinical trials of IMPLANON®a:
aBased on 3315 recording periods in 780 women, excluding the first 90 days after implant insertion. Bleeding/spotting episode = 1 or more consecutive days during which bleeding or spotting occurred.
NEXPLANON consists of a single, radiopaque, rod-shaped implant that contains 68 mg etonogestrel, pre-loaded in the needle of a disposable applicator. NEXPLANON is inserted subdermally, just under the skin at the inner side of the non-dominant upper arm.
NEXPLANON must be inserted by the expiration date printed on the packaging. NEXPLANON is a long-acting (up to 3 years), reversible, hormonal contraceptive method. The implant must be removed by the end of the third year and may be replaced by a new implant at the time of removal, if continued contraceptive protection is desired.
Click here to explore hypothetical patient profiles.
NEXPLANON provides pregnancy protection for up to 3 years.
NEXPLANON must be removed by the end of the third year and may be replaced by another NEXPLANON at the time of removal, if continued contraceptive protection is desired.
Yes, click here for the list of possible billing codes.
Due to the Affordable Care Act, NEXPLANON may be available to many women for $0 out-of-pocket expense.2–4,b
bThe cost of NEXPLANON depends on a patient’s insurance plan. Some patients may have coverage for NEXPLANON with out-of-pocket expenses, including a deductible, co-payment, or other charges. Patients may pay additional charges in connection with the insertion and/or removal of NEXPLANON (eg, office visit co-pay). You should confirm each patient’s coverage and cost-sharing obligations with the relevant payer.
In an analysis of representative commercial claims data, 98% of patient claims for NEXPLANON had $0 in out-of-pocket costs.4
This is based on data from over 49,000 patient claims for NEXPLANON in the Truven MarketScan® Commercial Claims dataset, January 2019 through December 2019.4
All HCPs performing insertions and/or removals of NEXPLANON should receive instructions and training prior to inserting or removing the implant.
How coverage status affects ordering and billing:
If NEXPLANON is covered as a medical benefit
If NEXPLANON is covered as a pharmacy benefit
If NEXPLANON is not covered
Click here for more information on ordering NEXPLANON.
CSCN = Customer Support Center for NEXPLANON; HCP = healthcare professional.
Click here for additional resources, including instructions for insertion and removal, training, patient counseling, and patient education.
In a clinical trial, mean insertion time was <1 minute (27.9±29.3 seconds). Insertion time was measured from the removal of the protective cap of the applicator until the retraction of the needle from the arm.
In a clinical study evaluating the insertion characteristics of the applicator for NEXPLANON5:
Out of 301 insertions of the NEXPLANON implant, the mean insertion time (from the removal of the protective cap of the applicator until retraction of the needle from the arm) was 27.9±29.3 seconds.
HCP = healthcare professional.
If you are seeking a copy of your original training certificate, you can contact the Organon Information Center for NEXPLANON at 1-877-467-5266.
If you are seeking a copy of the training certificate that was issued after completing the Mandatory Training Module following the October 2018 label update, you can access the certificate at nexplanontraining.com.
Once you log in, you will be able to access your certificate by clicking on the Training Certificates tab on the left-hand navigation. You will see an attachment for Training Certificate.
NPI = National Provider Identifier.
All HCPs should receive instructions and training prior to performing insertions and/or removals of NEXPLANON.
There is no cost for this training.
Click here to be redirected to nexplanontraining.com, where you can request training.
The approximately 2-hour session, which is sponsored by Organon, is not accredited for continuing medical education credit. The training is open only to MD/DO, NP, PA or CNMs, and residents authorized to perform the procedures entailed in the insertion and removal of NEXPLANON in the jurisdiction where they practice. Additionally, NPs, PAs, and CNMs must attest that they have met all specific state conditions and requirements, including but not limited to signing a collaborative agreement with an MD/DO. Residents must understand that they can only administer NEXPLANON under the supervision of an attending physician who has also been trained on the procedures to insert and remove NEXPLANON.
CNM = certified nurse midwife; DO = doctor of osteopathic medicine; HCP = healthcare professional; MD = medical doctor; NP = nurse practitioner; PA = physician assistant.
The Organon Information Center for NEXPLANON can be reached at 1-877-467-5266.
NEXPLANON is indicated for use by women to prevent pregnancy.
Complications of Insertion and Removal
Broken or Bent Implants
Changes in Menstrual Bleeding Patterns
Ectopic Pregnancies
Thrombotic and Other Vascular Events
Ovarian Cysts
Carcinoma of the Breast and Reproductive Organs
Liver Disease
Elevated Blood Pressure
Gallbladder Disease
Carbohydrate and Lipid Metabolic Effects
Depressed Mood
Return to Ovulation
Fluid Retention
Contact Lenses
Clinical Trial Experience
Effects of Other Drugs on Hormonal Contraceptives
Substances decreasing the plasma concentrations of hormonal contraceptives and potentially diminishing the efficacy of hormonal contraceptives:
Substances increasing the plasma concentrations of hormonal contraceptives:
Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) protease inhibitors and non-nucleoside reverse transcriptase inhibitors:
Effects of Hormonal Contraceptives on Other Drugs
USE IN SPECIFIC POPULATIONS
Pregnancy
Lactation
Pediatric Use
Overweight Women
Before prescribing NEXPLANON, please read the accompanying Prescribing Information. The Patient Information also is available.
1. Raymond EG. Contraceptive implants. In: Hatcher RA, Trussell J, Nelson AL, Cates Jr W, Steward F, Kowal D. Contraceptive Technology. 19th revised ed. New York, NY: Ardent Media, Inc. 2009.
2. Obama B. United States health care reform progress to date and next steps. JAMA. 2016;316(5):525–532. doi:10.1001/jama.2016.9797.
3. ASPE Issue Brief. The Affordable Care Act: promoting better health for women. US Department of Health and Human Services. Published June 14, 2016. Accessed September 7, 2023. https://aspe.hhs.gov/system/files/pdf/205066/ACAWomenHealthIssueBrief.pdf
4. Truven Commercial Claims & Encounters, 2019.
5. Mansour D, Mommers E, Teede H, et al. Clinician satisfaction and insertion characteristics of a new applicator to insert radiopaque Implanon: an open-label, noncontrolled, multicenter trial. Contraception. 2010;82(3):243–249.